Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), drawn from the whole corpus: 14 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cure rates for locally advanced HPV-negative disease have barely moved in twenty years.
No predictive biomarker beyond PD-L1, which is imperfect.
Function after laryngectomy, glossectomy and high-dose radiotherapy.
Second primaries and continued smoking after treatment.
Incidence still rising where tobacco and areca nut use are common.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 19 changes by month →When this page itself was last checked or edited.
Median EFS 59.
Three-year disease-free survival 63.
A milestone in how this cancer is treated.
EFS 19.
A milestone in how this cancer is treated.